SNX-5422 (mesylate)
SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.
Product Specifications
CAS Number
1173111-67-5
Product Name Alternative
PF-04929113 (mesylate)
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-04929113-Mesylate.html
Solubility
10 mM in DMSO
Smiles
CS(=O)(O)=O.O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C3=CC=C(C(N[C@@H]4CC[C@@H](OC(CN)=O)CC4)=C3)C(N)=O
Molecular Formula
C26H34F3N5O7S
Molecular Weight
617.64
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[3]Kim SH, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016 Feb;51 (2) :274-82.|[1]Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52 (14) :4288-305|[2]Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14 (1) :240-8.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HSP90
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![HES1 Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI1H8]](https://cdn.genprice.uk/products/937/68dd1b6d061270361ea16d53/imageurl/ta503958bm.webp)
TA503958BM 100 µL
HES1 Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI1H8]
Sign In for Pricing
View Details 
